Your session is about to expire
← Back to Search
Imaging Techniques for Multiple Sclerosis
Phase 2
Waitlist Available
Led By Burcu Zeydan, MD
Research Sponsored by Mayo Clinic
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline
Awards & highlights
No Placebo-Only Group
Summary
This trial tests if MRI + PET/CT scans can help diagnose MS & measure brain inflammation related to it.
Who is the study for?
This trial is for individuals with Multiple Sclerosis (MS) who are already part of certain MS studies or clinics, and healthy controls without inflammatory brain diseases. Participants must be able to lie still for imaging procedures and give consent. Pregnant or breastfeeding women, recent steroid users, and those with MRI safety risks like pacemakers can't join.
What is being tested?
The study is testing the effectiveness of combining MRI scans with PET/CT imaging using C-11 ER176 Radiotracer and C11 Pittsburgh Compound B to measure brain inflammation in people with MS.
What are the potential side effects?
While not explicitly listed, potential side effects may include discomfort from lying still during imaging, allergic reactions to radiotracers, and exposure to radiation from PET/CT scans.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 2 days
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 days
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Uptake of C-11 ER176 Radiotracer
Uptake of C-11 Pittsburgh compound-B (PiB) in white matter myelin
Secondary study objectives
Number of subjects with adverse events
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Experimental Treatment
Group I: Multiple Sclerosis GroupExperimental Treatment4 Interventions
Subjects with current diagnosis of Multiple Sclerosis or an InflammatoryDemyelinating Disease of the Central Nervous System will have a PET/CT scan with radiotracer drug C-11 PIB \& C-11 ER176
Group II: Healthy Control GroupExperimental Treatment4 Interventions
Subjects without inflammatory-demyelinating diseases of the central nervous system
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
PET/CT scan
2013
Completed Phase 1
~340
MRI
2009
Completed Phase 2
~2810
Find a Location
Who is running the clinical trial?
Mayo ClinicLead Sponsor
3,362 Previous Clinical Trials
3,065,761 Total Patients Enrolled
11 Trials studying Multiple Sclerosis
2,039 Patients Enrolled for Multiple Sclerosis
Burcu Zeydan, MDPrincipal InvestigatorMayo Clinic
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I haven't taken any steroids in the last 2 weeks.I do not have any inflammatory brain or spinal cord diseases.I am able to understand and sign a consent form.I can't stay still lying down for 20 minutes.
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Research Study Groups:
This trial has the following groups:- Group 1: Healthy Control Group
- Group 2: Multiple Sclerosis Group
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.